Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GANX | Common Stock | Purchase | $49.9K | +50K | $1.00 | 50K | Aug 9, 2024 | Direct | F2 | |
holding | GANX | Common Stock | 881K | Aug 9, 2024 | See footnote | F1 |
Id | Content |
---|---|
F1 | The Reporting Person is the ultimate shareholder of 1 MM & 1 PP AG, which is the direct beneficial owner of the securities. |
F2 | The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |